89bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
89bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
SAN FRANCISCO, Aug. 09, 2024 (GLOBE NEWSWIRE) -- 89bio, Inc. (the "Company" or "89bio") (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardiometabolic diseases, today announced that the Compensation Committee of the Company's Board of Directors approved the grant of non-qualified stock options to purchase an aggregate of 19,800 shares of the Company's common stock to two new employees and 350,000 shares of the Company's common stock to the newly-hired Chief Operating Officer, Francis Sarena (the "Inducement Grants") on August 5, 2024 (the "Grant Date"). The Inducement Grants have been granted pursuant to the Company's 2023 Inducement Plan (the "Plan"). The Inducement Grants were granted as an inducement material to these individuals entering into employment with 89bio in accordance with Nasdaq Listing Rule 5635(c)(4).
2024年8月9日，89bio公司（以下簡稱「公司」或「89bio」）（納斯達克股票代碼：ETNB）宣佈，公司董事會薪酬委員會於2024年8月5日（「授予日」）批准向兩名新僱員授予非合格股票期權，以購買公司普通股的總數共計19800股，並向新聘請的首席運營官弗朗西斯·塞雷納授予公司普通股350000股的期權（以下簡稱「誘因津貼授予」）。誘因津貼授予依據公司2023年誘因計劃（以下簡稱「計劃」）授予。根據納斯達克上市規則5635（c）（4）規定，誘因津貼授予是爲了促使這些人進入89bio公司就業而授予的重要誘因。
The Inducement Grants have an exercise price per share that is equal to the closing price of 89bio's common stock on the Grant Date. The Inducement Grants will vest over a four-year period, with 25% of the shares vesting on the one-year anniversary of the employee's start date, and thereafter the remainder of the shares vest in 12 equal quarterly installments, subject to each employee's continued employment with 89bio through the applicable vesting dates.
此次誘因授予的每股行權價格等於授予日89bio普通股的收盤價格，期權的行權期爲4年，其中行權期滿1週年時，公司普通股的25%將獲得行權，其餘普通股將在接下來的12個相等季度獲得行權，前提是員工能夠持續就職89bio 。
About 89bio
89bio is a clinical-stage biopharmaceutical company dedicated to the development of best-in-class therapies for patients with liver and cardiometabolic diseases who lack optimal treatment options. The company is in Phase 3 studies for its lead candidate, pegozafermin, for the treatment of metabolic dysfunction-associated steatohepatitis (MASH) and severe hypertriglyceridemia (SHTG). Pegozafermin is a specifically engineered, potentially best-in-class fibroblast growth factor 21 (FGF21) analog with unique glycoPEGylated technology that optimizes biological activity through an extended half-life. The company is headquartered in San Francisco. For more information, visit or follow the company on LinkedIn.
關於89bio 89bio是一家專注於爲患有肝臟和代謝性疾病的患者開發最佳療法的臨床階段生物製藥公司。該公司致力於通過臨床發展其領先候選藥物pegozafermin，用於治療代謝性功能障礙相關脂肪肝（MASH）和嚴重高三酰甘油血癥（SHTG）。Pegozafermin是一種經過特殊設計的、潛在的最佳成長因子21類似物（FGF21類似物），通過糖基PEG化技術優化生物活性，並具有延長半衰期的特點。公司總部位於舊金山。欲了解更多信息，請訪問www.89bio.com或關注該公司的
89bio是一家臨床階段的生物製藥公司，致力於爲患有肝臟和心血管代謝疾病，缺乏最佳治療方案的患者開發最好的治療方案。該公司目前正在爲其主要候選藥物pegozafermin開展三期研究，用於治療代謝紊亂相關的脂肪肝（MASH）和嚴重高甘油三酯血癥（SHTG）。Pegozafermin是經過特殊設計的潛在最佳類纖維生長因子21（FGF21）類似物，通過經過擴展的半衰期進行生物活性的全面優化。該公司總部位於舊金山。欲了解更多信息，請訪問 или關注公司的LinkedIn。
Investor Contact:
Annie Chang
89bio, Inc.
investors@89bio.com
投資者聯繫人：
Annie Chang
89bio公司
investors@89bio.com
PJ Kelleher
LifeSci Advisors, LLC
+1-617-430-7579
pkelleher@lifesciadvisors.com
PJ Kelleher
LifeSci Advisors，LLC
+1-617-430-7579
pkelleher@lifesciadvisors.com
Media Contact:
Sheryl Seapy
Real Chemistry
sseapy@realchemistry.com
媒體聯繫人：
Sheryl Seapy
Real Chemistry
sseapy@realchemistry.com
譯文內容由第三人軟體翻譯。
